Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Polycystic ovarian syndrome (PCOS) is characterized by elevated androgens such as testosterone. Clinical studies suggest that ketogenic diets lower the levels of androgens. The ketone 3-hydroxybutyrate (3-OHB) may play an important role in these effects and the main purpose of this study is to investigate whether a 3-OHB supplement acutely improves the hormonal and metabolic status in women with PCOS.
Polycystic ovary syndrome (PCOS) affects 5-18% of women and is characterized by the presence of two of three of the Rotterdam criteria: Hyperandrogenism (clinical or biochemical), irregular menstrual cycles, and polycystic ovary morphology, after exclusion of other conditions that mimic PCOS. PCOS is associated with elevated levels of luteinizing hormone (LH) and unaltered levels of the follicle stimulating hormone (FSH), which leads to the characteristic hyperandrogenism (high levels of testosterone), oligo- or anovulation, and a large number of premature follicles in the ovarian. Insulin resistance causes hyperinsulinemia that decreases sex hormone binding globulin (SHBG) levels and stimulates androgen production (e.g., elevated concentrations of testosterone). Ketogenic diets are characterized by a diet low in carbohydrates, and has shown beneficial effects on weight and hormonal status in women with PCOS. Whether these improvements are mediated by ketones (e.g., 3-hydroxybutyrate, 3-OHB) or other effects related to this diet is unknown. The main purpose of this study is to investigate whether a 3-OHB supplement acutely improves the hormonal and metabolic status in women with PCOS.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | 60 ml water (same taste as active comparator) at 10 pm the night before and 6 am on the day for blood sampling (8 am). |
|
| 3-OHB | Active Comparator | 60 ml 3-OHB (30 g) at 10 pm the night before and 6 am on the day for blood sampling (8 am). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 3-OHB (KE4) | Dietary Supplement | 60 ml (30 g) of 3-OHB |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Plasma concentration of testosterone | Paired t-test | 10 hours after first intervention |
| Measure | Description | Time Frame |
|---|---|---|
| plasma SHBG | 10 hours after first intervention | |
| plasma 3-OHB | 10 hours after first intervention | |
| plasma glucose |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nikolaj Rittig | University of Aarhus | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Diabetes and Hormone Diseases (DoH) | Aarhus N | 8200 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40393075 | Derived | Rittig N, Christiansen Arlien-Soborg M, Svart MV, Thomsen HH, Kirkegaard K, Greve VH, Nielsen MM, Stochholm K, Ornstrup MJ, Gravholt CH. Ketone supplementation acutely lowers androgen and glucose levels in women with polycystic ovary syndrome: a randomized clinical trial. Eur J Endocrinol. 2025 May 30;192(6):717-727. doi: 10.1093/ejendo/lvaf106. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007662 | Ketosis |
| ID | Term |
|---|---|
| D000138 | Acidosis |
| D000137 | Acid-Base Imbalance |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014867 | Water |
| ID | Term |
|---|---|
| D006878 | Hydroxides |
| D000468 | Alkalies |
| D007287 | Inorganic Chemicals |
| D000838 | Anions |
| D007477 |
Not provided
Not provided
Power calculation resulted in n=18 for the primary endpoint. We plan to include n= 20 to ensure statistical power and take dropouts, missing values etc into account.
Washout period of minimum 3 days.
Not provided
Not provided
Not provided
| water | Dietary Supplement | 60 ml water (added bitter taste) |
|
| 10 hours after first intervention |
| serum insulin | 10 hours after first intervention |
| plasma C-peptide | 10 hours after first intervention |
| plasma free fatty acids | 10 hours after first intervention |
| plasma triglycerides | 10 hours after first intervention |
| plasma cholesterol | 10 hours after first intervention |
| C reactive protein | 10 hours after first intervention |
| plasma cytokines (such as Tumor Necrotic Factor alpha, Interleukin 6, Lipopolysaccharide -binding protein, soluble CD163) | 10 hours after first intervention |
| plasma prolactin | 10 hours after first intervention |
| Plasma FSH | 10 hours after first intervention |
| Plasma LH | 10 hours after first intervention |
| plasma free testosterone | 10 hours after first intervention |
| plasma estradiol | 10 hours after first intervention |
| plasma keto-testosterone | 10 hours after first intervention |
| Homeostatic Model Assessment for Insulin Resistance | 10 hours after first intervention |
| Ions |
| D004573 | Electrolytes |
| D010087 | Oxides |
| D017601 | Oxygen Compounds |